DSG2 and prostate carcinoma: Furthermore, the results of the Kaplan-Meier biochemical recurrence free survival curves denote that patients with a reduced DSG2 expression phenotype have a worse prognosis and poorer clinical outcome than patients whose prostate carcinoma is characterized by a high DSG2 expression phenotype; a finding further confirmed by multivariate analysis.